AI Engines For more Details: Perplexity Kagi Labs You
Gastric Ulcers: Lansoprazole is commonly prescribed to heal and prevent the recurrence of gastric ulcers, which are sores that develop on the lining of the stomach. It works by reducing the production of stomach acid, allowing existing ulcers to heal and preventing new ulcers from forming.
Duodenal Ulcers: Duodenal ulcers are similar to gastric ulcers but develop in the first part of the small intestine, known as the duodenum. Lansoprazole is effective in healing and preventing duodenal ulcers by decreasing stomach acid production and promoting ulcer healing.
Gastroesophageal Reflux Disease (GERD): GERD is a chronic condition where stomach acid flows back into the esophagus, leading to symptoms such as heartburn, regurgitation, and chest pain. Lansoprazole is used to relieve symptoms and heal esophageal damage caused by GERD by reducing acid production in the stomach.
Erosive Esophagitis: Erosive esophagitis is a condition characterized by inflammation and damage to the lining of the esophagus due to chronic exposure to stomach acid. Lansoprazole helps heal the esophageal lining and alleviate symptoms associated with erosive esophagitis by suppressing acid secretion.
Zollinger-Ellison Syndrome: Zollinger-Ellison syndrome is a rare condition characterized by the overproduction of stomach acid, leading to severe peptic ulcers, reflux symptoms, and diarrhea. Lansoprazole is used to manage excessive acid production in patients with Zollinger-Ellison syndrome to control symptoms and prevent complications.
Helicobacter pylori Eradication: Lansoprazole is part of triple or quadruple therapy regimens used to eradicate Helicobacter pylori bacteria, which are implicated in the development of peptic ulcers and gastritis. Combined with antibiotics and sometimes bismuth compounds, lansoprazole helps eradicate the bacteria and promotes ulcer healing.
Nonsteroidal Anti-inflammatory Drug (NSAID)-Induced Ulcers: Lansoprazole is prescribed for individuals who require long-term NSAID therapy but are at risk of developing ulcers due to the drugs' irritating effects on the stomach lining. Lansoprazole helps prevent NSAID-induced ulcers by reducing stomach acid production.
Barrett's Esophagus: In some cases, lansoprazole may be used to manage Barrett's esophagus, a condition where the normal lining of the esophagus is replaced by tissue similar to the lining of the intestine. By reducing acid reflux, lansoprazole may help slow the progression of Barrett's esophagus.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| Acne | 0.2 | -0.2 | |
| ADHD | 3.7 | 0.9 | 3.11 |
| Age-Related Macular Degeneration and Glaucoma | 1 | 0 | 0 |
| Allergic Rhinitis (Hay Fever) | 2.1 | 0.9 | 1.33 |
| Allergies | 4.8 | 3.1 | 0.55 |
| Allergy to milk products | 2 | 0.5 | 3 |
| Alopecia (Hair Loss) | 1.4 | 1.4 | |
| Alzheimer's disease | 5 | 7.3 | -0.46 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3 | 1.2 | 1.5 |
| Ankylosing spondylitis | 3.7 | 2.5 | 0.48 |
| Anorexia Nervosa | 0 | 3.1 | 0 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.4 | 4.25 |
| Asthma | 1.5 | 0.9 | 0.67 |
| Atherosclerosis | 1.6 | 2 | -0.25 |
| Atrial fibrillation | 3.4 | 2.2 | 0.55 |
| Autism | 10.4 | 9.7 | 0.07 |
| Barrett esophagus cancer | 0.5 | 0.1 | 4 |
| benign prostatic hyperplasia | 0.4 | 0.4 | |
| Bipolar Disorder | 1.6 | 1.9 | -0.19 |
| Brain Trauma | 0.6 | 0.8 | -0.33 |
| Carcinoma | 3.6 | 2.4 | 0.5 |
| Celiac Disease | 2.1 | 2.8 | -0.33 |
| Cerebral Palsy | 0.8 | 1.8 | -1.25 |
| Chronic Fatigue Syndrome | 5.1 | 5.6 | -0.1 |
| Chronic Kidney Disease | 3 | 2.7 | 0.11 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 1.3 | -0.63 |
| Chronic Urticaria (Hives) | 1.6 | 1.8 | -0.13 |
| Coagulation / Micro clot triggering bacteria | 1.2 | 1.6 | -0.33 |
| Colorectal Cancer | 4.8 | 1.1 | 3.36 |
| Constipation | 2 | 1 | 1 |
| Coronary artery disease | 2.3 | 1 | 1.3 |
| COVID-19 | 9.6 | 13.8 | -0.44 |
| Crohn's Disease | 9.8 | 6.6 | 0.48 |
| cystic fibrosis | 1.1 | 1 | 0.1 |
| deep vein thrombosis | 1.1 | 1.1 | 0 |
| Depression | 7.7 | 7.3 | 0.05 |
| Dermatomyositis | 0.1 | 0.2 | -1 |
| Eczema | 1.3 | 1.6 | -0.23 |
| Endometriosis | 3.2 | 0.8 | 3 |
| Eosinophilic Esophagitis | 0.5 | 0.5 | |
| Epilepsy | 3.2 | 1.1 | 1.91 |
| Fibromyalgia | 2 | 3.8 | -0.9 |
| Functional constipation / chronic idiopathic constipation | 5.7 | 4.7 | 0.21 |
| gallstone disease (gsd) | 2.3 | 1.2 | 0.92 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.3 | 1.1 | 1.09 |
| Generalized anxiety disorder | 3 | 1.6 | 0.88 |
| giant cell arteritis | 0.5 | -0.5 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.5 | -0.5 | |
| Graves' disease | 0.9 | 1.9 | -1.11 |
| Halitosis | 0.8 | 0.1 | 7 |
| Hashimoto's thyroiditis | 3 | 0.9 | 2.33 |
| Hidradenitis Suppurativa | 1 | 1 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 3.5 | 1.5 | 1.33 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0 | 0 |
| hyperglycemia | 0.4 | 1.1 | -1.75 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.4 | 0.5 |
| hypersomnia | 0.9 | -0.9 | |
| hypertension (High Blood Pressure | 1.9 | 3.8 | -1 |
| Hypothyroidism | 1.6 | -1.6 | |
| Hypoxia | 0.4 | 0.4 | |
| IgA nephropathy (IgAN) | 4.3 | -4.3 | |
| Inflammatory Bowel Disease | 4.2 | 9.5 | -1.26 |
| Insomnia | 0.9 | 1.1 | -0.22 |
| Intelligence | 1.9 | 1 | 0.9 |
| Intracranial aneurysms | 1.3 | 0.4 | 2.25 |
| Irritable Bowel Syndrome | 3.4 | 3.2 | 0.06 |
| Liver Cirrhosis | 4.8 | 3.5 | 0.37 |
| Long COVID | 7.1 | 9.5 | -0.34 |
| Low bone mineral density | 1.3 | -1.3 | |
| Lung Cancer | 0.4 | 1.5 | -2.75 |
| ME/CFS with IBS | 0.9 | 3.5 | -2.89 |
| ME/CFS without IBS | 2.9 | 2 | 0.45 |
| Menopause | 0.7 | 0.7 | |
| Metabolic Syndrome | 8.9 | 7.9 | 0.13 |
| Mood Disorders | 10.5 | 7.7 | 0.36 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.5 | -4 |
| Multiple Sclerosis | 4.2 | 6.2 | -0.48 |
| Multiple system atrophy (MSA) | 0.3 | 1.2 | -3 |
| Neuropathy (all types) | 0.6 | 0.4 | 0.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.3 | 5 | -0.52 |
| NonCeliac Gluten Sensitivity | 0.2 | -0.2 | |
| Obesity | 8.5 | 3.5 | 1.43 |
| obsessive-compulsive disorder | 6.5 | 5.4 | 0.2 |
| Osteoarthritis | 2.2 | 0.5 | 3.4 |
| Osteoporosis | 2.1 | 0.9 | 1.33 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 2.7 | 5.5 | -1.04 |
| Polycystic ovary syndrome | 3.2 | 2.2 | 0.45 |
| Postural orthostatic tachycardia syndrome | 0.5 | 0.7 | -0.4 |
| Premenstrual dysphoric disorder | 1.1 | 0 | 0 |
| primary biliary cholangitis | 0.5 | 1.3 | -1.6 |
| Psoriasis | 5.1 | 2.3 | 1.22 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.6 | 4.2 | 1.05 |
| Rosacea | 1.7 | 1 | 0.7 |
| Schizophrenia | 6.1 | 2.7 | 1.26 |
| scoliosis | 0.5 | 1.5 | -2 |
| Sjögren syndrome | 1.9 | 3.5 | -0.84 |
| Sleep Apnea | 2.2 | 2.2 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 0.1 | 12 |
| Stress / posttraumatic stress disorder | 3.2 | 2.8 | 0.14 |
| Systemic Lupus Erythematosus | 4.8 | 2 | 1.4 |
| Tic Disorder | 1.5 | 2 | -0.33 |
| Tourette syndrome | 0 | 0.3 | 0 |
| Type 1 Diabetes | 4.3 | 3 | 0.43 |
| Type 2 Diabetes | 9.4 | 7.9 | 0.19 |
| Ulcerative colitis | 3.1 | 5.2 | -0.68 |
| Unhealthy Ageing | 7.2 | 2.2 | 2.27 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.